key: cord-0715045-b5f5pafg
authors: Valent, Francesca; Gongolo, Francesco
title: Will all SARS-CoV-2 seroprevalence surveys provide the right picture?
date: 2020-07-21
journal: Public Health
DOI: 10.1016/j.puhe.2020.07.020
sha: 3085b3a500943dd56e4eafb7fde7215857e216b7
doc_id: 715045
cord_uid: b5f5pafg

Abstract Objectives We discuss two main potential sources of bias that might affect the results of the Italian nationwide SARS-CoV-2 seroprevalence survey conducted by the Italian Ministry of Health and the National Institute of Statistics in a sample of 150,000 persons in 2,000 cities for epidemiological purposes, at the end of May-beginning of June 2020. Methods The first issue regards performance of serological tests. Comparing serological test results with real‐time reverse‐transcriptase polymerase chain reaction available in an area of the Italian Region Friuli Venezia Giulia, we suspect that test performance is less than optimal, but still acceptable for estimating prevalence of antibodies. The second issue regards participation bias, which might produce distorted estimates and reduce usefulness of the survey. Results We show that participation bias is possible in the Friuli Venezia Giulia Region and identify a number of potential causes. Conclusions We acknowledge the importance of good communication and careful planning for effective interventions.

In various countries experiencing the COVID-19 epidemic, surveys of SARS-CoV-2 seroprevalence are conducted to assess the actual spread of the SARS-CoV-2 infection in defined populations since the beginning of the epidemic. Real-time reverse-transcriptase polymerase chain reaction (RT-PCR) test for SARS-CoV-2 in upper respiratory specimens collected through swabs is recommended by the World Health Organization for clinical management and outbreak control purposes [1] and is currently the gold standard for the etiological diagnosis of SARS-CoV-2 infection. However, incidence and prevalence data based on those tests are not representative of the general population experience for a number of reasons. First, swabs are only collected from either symptomatic persons or from people with increased risk of infection (e.g., close contacts of COVID-19 cases, health care professionals, etc.). In addition, the intensity or capacity of swab collection, which may be highly variable from one geographical area to another, affect the likelihood of detecting people who are infected at a certain time. Finally, RT-PCR can detect viral RNA in a respiratory specimen at the time of swab collection, thus results of the test only apply to that specific moment.

In Italy, 60 million inhabitants, the Ministry of Health and the National Statistical Institute ISTAT, in collaboration with the Italian Red Cross, planned a nationwide seroprevalence survey: a sample of 150,000 people was to be tested in 2,000 towns and cities, split by sex, occupation and six age classes [2] , from May 25, 2020 and for approximately 10 days. The sample was planned to be representative of each of the 20 Italian Regions. For example, in the 1,200,000-inhabitant Region Friuli Venezia Giulia (FVG), 6232 subjects had to be surveyed in approximately ten days [3] . The survey was established through Legislative Decree 30 of May 10, 2020 and funded with public money for more than 4 million Euro. The theoretical benefits of this survey are extremely important from a public health point of view and results might 3 influence policy makers' decisions in the upcoming months. There are two main issues, however, that should be considered when interpreting results: serological test performance and survey participation bias.

In the absence of published research on the validity of serological tests, we retrospectively Table 1 shows time intervals from first swab collection to blood withdrawal for discordant cases. Keeping in mind timing and the fact that RT-PCR on specimens collected through swabs cannot be considered a real gold standard since it may also be fallacious, our data suggest that evidence provided by serological tests seems to be less than perfect since false negative and false positive results likely exist.

Nonetheless, at least for population-level epidemiological purposes, serological test performance may be acceptable, in the absence of other reliable sources of information [4] . 4 After the start of the nationwide Italian survey, in FVG 1835 blood samples were collected from May 27 to June 10, less than 30% of the planned sample size. Potential participants had to be invited by the Italian Red Cross through a telephone call from a number, not well advertised before the beginning of the survey, starting as 065510, which could have been misinterpreted as a spam phone call, reducing responses. In addition, attending ambulatories for blood withdrawal might be considered unsafe by part of the population. Given the scarce adherence, the Red Cross prosecuted the telephone calls to potential participants beyond the originally planned 10 days and further 446 subjects were enrolled as of June 26. Thus, 2281 subjects were enrolled overall, 36.6% of the planned sample. In FVG, participation was low, reducing precision of the estimates in the Region. In addition, selection bias was likely, affecting validity. In fact, participation differed by geographical area (the relative distribution in three regional sub-areas was respectively 40.4%, 25.8%, and 33.7% for the potential survey sample vs 45.5%, 28.7%, and 25.7% for actual participants). In addition, since subjects with positive serological tests are temporarily isolated (as reported in the survey information sheet), those who had just restarted working after several weeks of lockdown might have not consented to participate, to avoid the risk of a new period of inactivity and lost income. Finally, in FVG, the population was additionally requested to participate, when presenting for the blood withdrawal, in an independent social survey promoted by the FVG Regional Administration, aiming at linking serological results with personal behaviors [5] , as advertised in the local media. The burden of an additional survey and the possibility that one's personal data and sensitive information could be communicated to others might have further discouraged participation, in a non-random fashion.

Thus, in the FVG Region, despite test accuracy may still be acceptable to assess the spread of SARS-CoV-2 infection in the population, participation bias may distort estimates. Even in an emergency situation as the one caused by COVID-19, good communication and careful 7 

Laboratory testing for coronavirus disease (COVID-19) in suspected human cases

Protocollo metodologico per un'indagine di siero-prevalenza sul SARS-CoV-2 condotta dal Ministero della salute e dall'ISTAT. Decreto Legge 10 maggio 2020 n.30

Waiting for Certainty on Covid-19

Antibody Tests -At What Cost?

Fase 2: conoscere nuova normalità, al via indagine in Fvg

planning are crucial for effective interventions. When interpreting results of seroprevalence surveys, particular attention should be devoted to the assessment of potential sources of bias.

Competing interests: None declared Ethical approval: Not required. All procedures contributing to this work comply with the Declaration of Helsinki. The analyses were based on anonymous administrative data, therefore patient consent and Ethical Committee approval were not required in Italy.